6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Published on
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For
the
month of May, 2006.
Commission
File Number ________________
Novogen
Limited
(Translation
of registrant’s name into English)
140
Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F
x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a
Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes o No
o
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Novogen
Limited
(Registrant)
/s/
Ron Erratt
Ronald
Lea Erratt
Company
Secretary
Date
25 May, 2006
ASX
& MEDIA RELEASE
25
MAY, 2006
NOVOGEN
LIMITED APPOINTS NEW DIRECTOR
Novogen
Limited (ASX: NRT Nasdaq: NVGN) has appointed Professor Alan Husband PhD,
DSc
FASM to its board as an Executive Director.
Professor
Husband has more than 30 years experience in basic and applied scientific
research and research management.
His
academic research interests in immunology and pathology have been reflected
in
the publication of several books and more than 200 scientific papers and
he
currently holds a professorial appointment at the University of Sydney.
These
activities in basic and applied research, coupled with experience in the
biotechnology industry, provided the foundations for his current appointment
as
Group Director of Research for the Novogen Group of companies, which he has
held
since 1996.
In
this
position Professor Husband is responsible for the development and
commercialisation of the Company’s flavonoid drug technology platform.
During
this time he has managed the scientific discovery and clinical trial programs,
including development of novel oncology, cardiovascular and anti-inflammatory
therapeutics as well as wound healing technologies.
Welcoming
Professor Husband to the board, Novogen’s Chairman, Philip Johnston, said the
input of his extensive scientific expertise and knowledge of the Company’s
Research and Development would provide a valuable contribution and addition
at
Board level.
Professor
Husband joins the Novogen Board of directors which includes Mr Philip Johnston
(Chairman), Mr Christopher Naughton (CEO), Mr Peter Simpson, Professor Paul
Nestel AO, Dr Leanna Read and Mr Geoff Leppinus.
ISSUED
FOR:
NOVOGEN LIMITED
LISTINGS: ASX
(CODE NRT), NASDAQ (CODE NVGN).
FOR
FURTHER
INFORMATION: CHRISTOPHER
NAUGHTON, MANAGING DIRECTOR, NOVOGEN LIMITED
TEL
(02) 9878 0088 http://www.novogen.com
ISSUED
BY :
WESTBROOK
COMMUNICATIONS
CONTACT:
DAVID REID TEL (02) 9231 0922 OR 0417 217 157
Rule
3.19A.1
Appendix
3X
Initial
Director’s Interest Notice
Information
or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX’s property and may be made
public.
Introduced
30/9/2001.
|
Name
of entity: NOVOGEN
LIMITED
|
|
ABN:
37
063 259 754
|
We
(the
entity) give ASX the following information under listing rule 3.19A.1 and
as
agent for the director for the purposes of section 205G of the Corporations
Act.
|
Name
of Director
|
ALAN
JAMES HUSBAND
|
|
Date
of appointment
|
23
MAY, 2006
|
Part
1 - Director’s
relevant interests in securities of which the director is the registered
holder
In
the case of a trust, this includes interests in the trust made available
by the
responsible entity of the trust
|
Number
& class of securities
61,148
ORDINARY SHARES
|
Part
2 - Director’s relevant interests in securities of which the director is not the
registered holder
In
the case of a trust, this includes interests in the trust made available
by the
responsible entity of the trust
|
Name
of holder & nature of interest
Note:
Provide details of the circumstances giving rise to the relevant
interest.
|
Number
& class of Securities
NIL
|
Part
3 - Director’s interests in contracts
|
Detail
of contract
|
NIL
|
|
Nature
of interest
|
NIL
|
|
Name
of registered holder
(if
issued securities)
|
NIL
|
|
No.
and class of securities to which interest relates
|
NIL
|
25
MAY,
2006